Indications
Xenleta is indicated for the treatment of community-acquired pneumonia (CAP) in adults when it is considered inappropriate to use antibacterial agents that are commonly recommended for the initial treatment of CAP or when these have failed. Consideration should be given to official guidance on the appropriate use of antibacterial agents.
Composition
- Active substance
- lefamulin acetate
- International name (INN)
- lefamulin
Official product information
The European public assessment report holds the summary of product characteristics and the package leaflet in every EU language.
Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.
At a glance
- Medicine
- Xenleta
- Active substance
- lefamulin acetate
- ATC code
- J01XX
- Therapeutic area
- Pneumonia, Bacterial, Community-Acquired Infections